News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Year All Years 2019 2018 2017 2016 2015 Keywords Go

Advanced Search

Search

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Jul 2, 2019

  InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
• May 15, 2019

  InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
• May 8, 2019

  InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019
• Mar 18, 2019

  InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
• Mar 13, 2019

  InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
• Mar 12, 2019

  InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019
• Mar 6, 2019

  InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board
• Feb 12, 2019

  InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
• Feb 5, 2019

  InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
• Jan 11, 2019

  InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer
• Jan 3, 2019

  InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019
• Dec 4, 2018

  InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program
• Nov 12, 2018

  InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
• Nov 5, 2018

  InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018
• Nov 5, 2018

  InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls
• Oct 10, 2018

  InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
• Oct 3, 2018

  InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up
• Sep 25, 2018

  InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
• Sep 13, 2018

  InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
• Sep 11, 2018

  InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
• Sep 10, 2018

  InMed Files Patent Application for its Cannabinoid Biosynthesis Program
• Sep 7, 2018

  InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
• Aug 31, 2018

  InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
• Aug 1, 2018

  InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
• Jun 21, 2018

  InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option

Show 5102550100 per page